Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 01 2023 - 8:00AM
Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, today announced that it
has granted inducement stock options to purchase an aggregate of
7,360 shares of its common stock to two new employees. The
inducement stock options have a grant date of February 28, 2023 and
were granted as inducements material to the new employees entering
into employment with Biocept in accordance with Nasdaq Listing Rule
5635(c)(4).
The inducement stock options have an exercise price of $0.52 per
share, the closing price of Biocept’s common stock on February 28,
2023, are non-qualified stock options, have a ten-year term and
vest over four years, with 25% of the shares vesting on the
one-year anniversary of the vesting commencement date and the
remaining 75% of the shares vesting in equal monthly installments
over the following 36 months, subject to the new employees’
continued service with Biocept through the applicable vesting
dates. The inducement stock options are subject to the terms and
conditions of Biocept’s Amended and Restated 2013 Equity Incentive
Plan, as amended.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers. For more information, visit www.biocept.com.
Follow Biocept on Facebook, LinkedIn, Twitter, and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230301005402/en/
Investor and Media Contact: Jody Cain, LHA Investor
Relations Jcain@lhai.com, 310-691-7100
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Sep 2023 to Sep 2024